soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo The Role of Glucagon-Like Peptide-1

Healthcare providers may recommend starting with a lower dose and gradually increasing it based on observed effects and patient tolerance

Comparing total cost of carenot just monthly injection or tablet priceensures you select a provider model that supports safe, monitored treatment alongside affordability

For people interested in an alternative drug to Ozempic, some alternatives include Wegovy, Rybelsus, Mounjaro, Trulicity, and metformin

Cardiovascular Benefits: Some studies suggest that semaglutide may have cardiovascular benefits beyond its effects on weight and blood sugar levels

Additionally, Mounjaro may also offer benefits for weight management and can be prescribed in such cases

The failure to address this issue has compounded the environmental and public health crisis in affected communities